Close Menu

NEW YORK – Israeli precision oncology and proteomics startup OncoHost said on Tuesday it has raised $8 million in a Series B funding round, led by investment platform OurCrowd.

The company uses proteomic analysis combined with machine learning on patient blood samples to better understand their response to therapy and detect signs of resistance to treatment through the company's Prophet platform. The funding will be used to finance OncoHost's clinical trials, open a US-based affiliate, and launch Prophet.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.